Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Primary Ciliary Dyskinesia: early-phase trial registry

4 of 8 indexed Primary Ciliary Dyskinesia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Primary Ciliary Dyskinesia: 8 US clinical trials tracked, 4 recruiting.

Primary Ciliary Dyskinesia is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is ReCode Therapeutics, running 2 of these trials.

Enrollment posture brief

Registry condition primary-ciliary-dyskinesia

OPEN 4 | RECR 50% | LATE 0 | EARLY 1 | RANK #2176 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Activity, Motor75%Achalasia50%Primary Ciliary Dyskines (th…50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Primary Ciliary Dyskinesia

Primary Ciliary Dyskinesia lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Primary Ciliary Dyskinesia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Primary Ciliary Dyskinesia is recruiting above its size-band peers.

    4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Primary Ciliary Dyskinesia research.

    ReCode Therapeutics accounts for 2 of 8 trials (25%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Primary Ciliary Dyskinesia enrolment sits around 105 participants.

    Median target enrolment is 105 among the 8 trials that report a genuine target (sentinel values excluded). 4 of those (50%) plan for fewer than 100 participants.

  4. Primary Ciliary Dyskinesia research leans observational.

    3 interventional and 5 observational studies make up this index (37.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Primary Ciliary Dyskinesia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Technetium99m - Sulfur Colloid (Tc99m-SC) Diagnostic test
1 trials
Sano Genetics Testing Kit Genetic
1 trials
MRI of the chest Diagnostic test
1 trials
CT of the chest Diagnostic test
1 trials
Mucociliary Clearance (MCC) Diagnostic test
1 trials
Multiple Breath Washout (MBW) Diagnostic test
1 trials
Albuterol Drug
1 trials
Nasal Nitric Oxide testing Device
1 trials

US sites by state

Facility locations filed on Primary Ciliary Dyskinesia trials. A trial with sites in several states counts in each.

North Carolina 3 trials
California 2 trials
Washington 1 trials
Tennessee 1 trials
Missouri 1 trials
Indiana 1 trials
Connecticut 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Primary Ciliary Dyskinesia page

8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Primary Ciliary Dyskinesia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • ReCode Therapeutics sponsors the most Primary Ciliary Dyskinesia trials on record, review their full trial history before evaluating a specific study. See ReCode Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Ciliary Dyskinesia condition card totals 8 registered trials; most-linked intervention Technetium99m - Sulfur Colloid (Tc99m-SC); top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.